pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Risperdal Consta
drug
save

risperidone PR

Marketedupdated 3mo ago
by Johnson & Johnson Innovative Medicine
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval42 co-mentions · 21 sources
  • drugrisperidone ER29 co-mentions · 21 sources
  • drugrisperidone29 co-mentions · 21 sources
  • drugrisperidone ODT21 co-mentions · 21 sources
  • tagSmall Molecule13 co-mentions · 13 sources

all catalysts(0)

nothing on the calendar yet

Trials studying risperidone PR

  • phase3Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medicationsrecruitingn=380
  • phase4An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatmentcompletedn=31
  • —Long-term Antipsychotic Pediatric Safety Trialcompletedn=509
  • phase2Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)completedn=499
  • phase3Long-Term Study of MP-214 in Patients With Schizophreniacompletedn=254
  • phase3Safety and Efficacy of MP-214 in Patients With Schizophreniacompletedn=512
  • phase3A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophreniacompletedn=125
  • —Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapsecompletedn=275
more trials →

News(0)

no news has mentioned this drug yet

brand
Risperdal Consta
generic
risperidone
indication
Bipolar Disorder (Manic Depression)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 20m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?